20 306

Cited 0 times in

A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia

 Han Saem Jeong  ;  Soon Jun Hong  ;  Jin-Man Cho  ;  Ki Hoon Han  ;  Dong-Hun Cha  ;  Sang-Ho Jo  ;  Hyun-Jae Kang  ;  So-Yeon Choi  ;  Cheol Ung Choi  ;  Eun Jeong Cho  ;  Young-Hoon Jeong  ;  Hyeon-Cheol Gwon  ;  Byeong-Keuk Kim  ;  Sung Yun Lee  ;  Sang-Hyun Kim  ;  Jeong Cheon Ahn  ;  Young Joon Hong  ;  Woo-Shik Kim  ;  Seong-Ill Woo  ;  Tae-Ho Park  ;  Kyoo-Rok Han 
 CLINICAL THERAPEUTICS, Vol.44(10) : 1310-1325, 2022-10 
Journal Title
Issue Date
Anticholesteremic Agents* / adverse effects ; Cholesterol, LDL ; Double-Blind Method ; Drug Therapy, Combination ; Dyslipidemias* / diagnosis ; Dyslipidemias* / drug therapy ; Ezetimibe / adverse effects ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects ; Hypercholesterolemia* / drug therapy ; Male ; Treatment Outcome
ezetimibe ; hypercholesterolemia ; pitavastatin
Purpose: Pitavastatin is a unique lipophilic statin with moderate efficacy in lowering LDL-C levels by 30% to 50% with a tolerable safety profile. However, the efficacy of adding ezetimibe to pitavastatin in patients with dyslipidemia has not been well investigated. Therefore, the objective of this double-blind, multicenter, randomized, Phase III study was to compare the efficacy and safety of pitavastatin and ezetimibe combination therapy with those of pitavastatin monotherapy in Korean patients with primary hypercholesterolemia.

Methods: Korean men and women aged >19 and <80 years with primary hypercholesterolemia requiring medical treatment were included in this study. During the 8-week screening period, all patients were instructed to make therapeutic lifestyle changes. The screening period consisted of a 4-week washout period and a placebo run-in period (4-8 weeks). During treatment period I, patients were randomly assigned to receive 1 of 4 treatments: pitavastatin 2 mg plus ezetimibe 10 mg, pitavastatin 2 mg, pitavastatin 4 mg plus ezetimibe 10 mg, or pitavastatin 4 mg. The 8-week double-blind treatment period then commenced. Adverse events (AEs), clinical laboratory data, and vital signs were assessed in all patients.

Findings: The percentages in LDL-C from baseline after 8 weeks of double-blind treatment decreased significantly in the pooled pitavastatin/ezetimibe (-52.8% [11.2%]) and pooled pitavastatin (-37.1% [14.1%]) groups. Treatment with pitavastatin/ezetimibe resulted in a significantly greater LDL-C-lowering effect than that with pitavastatin (difference, -15.8 mg/dL; 95% CI, -18.7 to -12.9; P < 0.001). The precentages of achieving LDL-C goal in pooled pitavastatin/ezetimibe and pooled pitavastatin groups were 94.2% and 69.1%, respectively (P < 0.001). There were no significant differences in the incidence of overall AEs and adverse drug reactions. Serious AEs were comparable between the groups.

Implications: Pitavastatin and ezetimibe combinations effectively and safely decreased LDL-C levels by >50% in patients with dyslipidemia. The safety and tolerability of pitavastatin and ezetimibe combination therapy were comparable with those of pitavastatin monotherapy.

Clinicaltrials: gov identifier: NCT04584736.
Files in This Item:
T9992022745.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Byeong Keuk(김병극) ORCID logo https://orcid.org/0000-0003-2493-066X
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.